Dayvigo (Lemborexant) Cost in Missouri 2026: Prices, Insurance, Savings

Lemborexant (brand name Dayvigo) is an oral dual orexin receptor antagonist (DORA) that received FDA approval in December 2019 for adult insomnia treatment. It is dispensed as 5 mg and 10 mg tablets, each taken once per night, and carries Schedule IV controlled substance classification. Unlike earlier sedative-hypnotics such as zolpidem (Ambien) and benzodiazepine receptor agonists, lemborexant works through a distinct pharmacological pathway and represents one of two FDA-approved DORAs, the other being suvorexant (Belsomra) 1.

The useful question for a Missouri patient is not "what does Dayvigo cost" but "which access channel applies to me," because the answer changes by hundreds of dollars a month. A patient with commercial insurance and a manufacturer savings card, a patient on MO HealthNet (Missouri Medicaid), and an uninsured cash-pay patient are effectively pricing three different products. Any single quoted dollar figure for Dayvigo is a snapshot of one channel at one moment, not a stable fact about the drug.

What is actually stable versus what changes

Some facts about Dayvigo are fixed by FDA regulatory status and do not depend on the date you check them: it is approved for insomnia in adults, it comes in two tablet strengths, and it is a Schedule IV controlled substance. Other facts, like what a specific Missouri pharmacy charges in cash, what a specific commercial plan requires for prior authorization, or whether MO HealthNet will approve an exception, are date-sensitive and plan-specific. A page claiming a single national or state "average price" for a brand-name drug with no generic is describing a moving target, not a fact you can act on months later.

Cash-pay pricing at Missouri pharmacies

Dayvigo's manufacturer list price and typical discounted cash prices at retail chains, warehouse clubs, and discount-coupon platforms like GoodRx change over time and differ by pharmacy. We do not have a verified, dated source for a specific Missouri average cash price, and presenting an unverified number as a fixed fact would mislead readers who are budgeting a monthly prescription cost. If you need a current number, the reliable approach is to call two or three Missouri pharmacies (a chain, an independent, and a warehouse club if one is nearby) and check a discount-coupon app the same week you plan to fill the prescription, since these prices are updated frequently and can shift by tens of dollars month to month.

What is reasonably certain: because there is no FDA-approved generic lemborexant identified as of this draft, cash prices for Dayvigo will run substantially higher than for generic Z-drugs such as zolpidem, which are inexpensive because of generic competition. That relative gap is a structural fact tied to patent and generic-approval status, not a specific dollar figure.

Missouri Medicaid (MO HealthNet) coverage

State Medicaid programs, including MO HealthNet, commonly restrict coverage of newer brand-name insomnia drugs like Dayvigo when older, cheaper agents are available on the preferred formulary. Whether MO HealthNet covers Dayvigo at all, under what diagnosis codes, and with what prior authorization criteria, is a formulary detail that changes and needs to be confirmed directly against MO HealthNet's current preferred drug list rather than assumed from a general pattern. If a prescriber believes a patient's insomnia and a comorbid condition interact in a way that supports a coverage exception, that argument needs to be built from that patient's actual clinical picture and current guideline literature, not from a claim reproduced from an unverified secondary source.

If MO HealthNet declines to cover Dayvigo, agents on the preferred formulary, such as suvorexant or older sedating medications, are the practical alternative to discuss with a prescriber. Which of those is appropriate depends on the individual's sleep disorder profile, other medications, and comorbidities, and is a clinical decision, not a pricing one.

Commercial insurance in Missouri

Commercial insurers generally place brand-name insomnia medications with no generic competitor on a non-preferred or specialty formulary tier, which usually means the patient will encounter prior authorization requirements and possibly step therapy (documentation that a cheaper first-line drug, such as a Z-drug or a sedating antidepressant, was tried first or is contraindicated). Specific insurer names, tier placements, and copay ranges change by plan year and were not verified against a current Missouri formulary document for this draft, so we are not restating them as fixed facts here. The practical path if a plan denies coverage: ask for the written denial reason, and if it is based on step therapy, ask your prescriber whether a peer-to-peer review with the plan's medical director is appropriate, since this often resolves first-round denials for this drug class.

Manufacturer savings and patient assistance programs

Eisai, the company that markets Dayvigo, has historically offered a commercial-insurance savings card program and a separate patient assistance program for uninsured or underinsured patients, similar to programs offered by many manufacturers of branded, no-generic drugs. Eligibility rules, dollar caps, and which pharmacies participate change and are set by the manufacturer, not by us. Before assuming a specific out-of-pocket number from any savings program, check Eisai's current program terms directly, since manufacturer copay programs are excluded for anyone using Medicare, Medicaid, or other government-funded insurance, and program terms are revised periodically.

Compounded lemborexant

Lemborexant is not currently listed among substances the FDA has designated as ineligible for compounding, so a licensed 503A pharmacy can, in principle, compound a patient-specific lemborexant preparation from a valid prescription, though this status should be confirmed directly with current FDA compounding guidance. This is meaningfully different from the FDA-approved Dayvigo tablet: compounded preparations do not go through FDA review for safety, effectiveness, or bioequivalence, and potency or absorption can vary by pharmacy and batch. A prescriber has to write a prescription that specifically calls for a compounded formulation; a standard Dayvigo prescription cannot simply be filled as a compound.

If you are considering a compounded version because of cost, verify that the pharmacy carries pharmacy compounding accreditation (for example, through PCAB or ACHC) and ask what quality testing it performs on each batch. Reported prices for compounded lemborexant vary by pharmacy and were not independently verified for this draft; treat any specific number you see quoted online as a starting point for a phone call, not a confirmed price.

Telehealth prescribing

Missouri-licensed prescribers can generally evaluate and prescribe controlled substances, including Schedule IV drugs like lemborexant, through telehealth, subject to state telehealth practice requirements and federal DEA rules governing remote prescribing of controlled substances. Federal telemedicine flexibilities for controlled-substance prescribing have been extended and revised multiple times in recent years, so the current rule in effect on any given date needs to be checked against the DEA's own guidance rather than assumed from an older summary. What has not changed is that a prescriber must still conduct a clinical evaluation adequate to establish an insomnia diagnosis, which typically includes screening for conditions like obstructive sleep apnea that can mimic or worsen insomnia.

How Dayvigo compares to other options, and where the evidence stands

The mechanism of lemborexant involves antagonism of orexin receptors, which suppresses wake-promoting neuropeptide signaling. This represents a fundamentally different approach from Z-drugs and benzodiazepine receptor agonists, which potentiate GABA neurotransmission. The FDA's December 2019 approval rested on randomized controlled trials that evaluated lemborexant against both placebo and active comparators in adults with insomnia disorder; comprehensive trial results appear in the FDA label 1. Specific efficacy metrics (sleep latency changes in minutes, statistical significance levels, participant numbers) are not included in this summary because source verifications for previously cited values could not be confirmed; clinicians requiring such quantitative data should consult the FDA-approved label directly or refer to published pivotal trial manuscripts.

Established: lemborexant is FDA-approved for insomnia in adults, is mechanistically distinct from Z-drugs, and has no confirmed generic competitor as of this draft. Plausible but not something we can confirm here in specific numeric terms: comparative advantages over Z-drugs in older adults regarding next-day sedation or fall risk, which is a real and actively discussed clinical question but needs to be checked against current geriatric prescribing guidance for the individual patient rather than a blanket claim. Not established from anything in this article: any specific cost figure, insurer copay, or MO HealthNet coverage rule as a fixed, dated fact, because those change and were not verified against a current primary source.

Verification checklist: what to trust as-is versus what to re-check before paying

Use this before you commit to a pharmacy, insurance path, or compounding pharmacy for Dayvigo/lemborexant in Missouri.

Stable facts (unlikely to change; verify once against the FDA label if needed)

• Lemborexant is FDA-approved for insomnia in adults, available as 5 mg and 10 mg tablets, taken once nightly.
• Dayvigo is a Schedule IV controlled substance under federal law.
• Lemborexant's mechanism (orexin receptor antagonism) differs from Z-drugs and benzodiazepines.
• Compounding of lemborexant by a 503A pharmacy is not blocked by an FDA "difficult to compound" or bulk substance exclusion as of the FDA's current list.

Date-sensitive facts (re-check every time, ideally the same week you fill or enroll)

• Manufacturer list price and any cash-pay average at a specific Missouri pharmacy.
• Whether a generic lemborexant has since received FDA approval.
• MO HealthNet's current formulary status and prior authorization criteria for Dayvigo.
• Your specific commercial plan's tier placement, copay, and step therapy requirements for Dayvigo this plan year.
• Eisai's savings card and patient assistance program eligibility rules and dollar caps.
• Current DEA and Missouri rules on telehealth prescribing of Schedule IV controlled substances.
• Accreditation status (PCAB, ACHC) and pricing of any specific 503A compounding pharmacy you are considering.

Who to ask, not just what to search

• Pharmacy benefit manager or insurer member services, for current tier and prior authorization rules.
• MO HealthNet provider services or your prescriber's office, for current Medicaid formulary status.
• Eisai's own patient support line or website, for current savings card and assistance program terms.
• The specific compounding pharmacy's pharmacist, for accreditation, testing, and current pricing.

When to seek care instead of shopping for price

Cost-shopping should not delay evaluation for insomnia that is severe, worsening, or accompanied by loud snoring, witnessed pauses in breathing, excessive daytime sleepiness, or new mood or cognitive changes. Those symptoms warrant a clinical evaluation, potentially including a sleep study, before deciding which medication and which cost pathway make sense. If a patient using lemborexant or any sleep medication develops severe daytime drowsiness, difficulty waking, sleep-related behaviors they do not remember, or signs of a severe allergic reaction, that requires urgent medical attention rather than a pharmacy price comparison.